SRC and breast carcinoma: One notable function of c-Met is its interaction with the oncogenic tyrosine kinase c-Src, creating a mechanism to bypass inhibited EGFR signaling in breast cancer cell lines [20] as well as increasing resistance to c-Src inhibitory drugs in HNSCC [21].